Fatal Anaphylaxis: Mortality Rate and Risk Factors

Paul J. Turner, Elina Jerschow, Thisanayagam Umasunthar, Robert Lin, Dianne E. Campbell, Robert J. Boyle

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Up to 5% of the US population has suffered anaphylaxis. Fatal outcome is rare, such that even for people with known venom or food allergy, fatal anaphylaxis constitutes less than 1% of total mortality risk. The incidence of fatal anaphylaxis has not increased in line with hospital admissions for anaphylaxis. Fatal drug anaphylaxis may be increasing, but rates of fatal anaphylaxis to venom and food are stable. Risk factors for fatal anaphylaxis vary according to cause. For fatal drug anaphylaxis, previous cardiovascular morbidity and older age are risk factors, with beta-lactam antibiotics, general anesthetic agents, and radiocontrast injections the commonest triggers. Fatal food anaphylaxis most commonly occurs during the second and third decades. Delayed epinephrine administration is a risk factor; common triggers are nuts, seafood, and in children, milk. For fatal venom anaphylaxis, risk factors include middle age, male sex, white race, cardiovascular disease, and possibly mastocytosis; insect triggers vary by region. Upright posture is a feature of fatal anaphylaxis to both food and venom. The rarity of fatal anaphylaxis and the significant quality of life impact of allergic conditions suggest that quality of life impairment should be a key consideration when making treatment decisions in patients at risk for anaphylaxis.

Original languageEnglish (US)
Pages (from-to)1169-1178
Number of pages10
JournalJournal of Allergy and Clinical Immunology: In Practice
Volume5
Issue number5
DOIs
StatePublished - Sep 1 2017

Fingerprint

Anaphylaxis
Mortality
Venoms
Food
Quality of Life
Mastocytosis
Seafood
General Anesthetics
Nuts
Fatal Outcome
Food Hypersensitivity
Age Factors
beta-Lactams
Posture
Pharmaceutical Preparations
Epinephrine
Insects
Anesthetics
Decision Making
Milk

Keywords

  • Anaphylaxis
  • Drug allergy
  • Food allergy
  • Insect sting
  • Mortality

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Fatal Anaphylaxis : Mortality Rate and Risk Factors. / Turner, Paul J.; Jerschow, Elina; Umasunthar, Thisanayagam; Lin, Robert; Campbell, Dianne E.; Boyle, Robert J.

In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 5, No. 5, 01.09.2017, p. 1169-1178.

Research output: Contribution to journalArticle

Turner, Paul J. ; Jerschow, Elina ; Umasunthar, Thisanayagam ; Lin, Robert ; Campbell, Dianne E. ; Boyle, Robert J. / Fatal Anaphylaxis : Mortality Rate and Risk Factors. In: Journal of Allergy and Clinical Immunology: In Practice. 2017 ; Vol. 5, No. 5. pp. 1169-1178.
@article{28cea135e06f447fbddfeb3f8c80eb5a,
title = "Fatal Anaphylaxis: Mortality Rate and Risk Factors",
abstract = "Up to 5{\%} of the US population has suffered anaphylaxis. Fatal outcome is rare, such that even for people with known venom or food allergy, fatal anaphylaxis constitutes less than 1{\%} of total mortality risk. The incidence of fatal anaphylaxis has not increased in line with hospital admissions for anaphylaxis. Fatal drug anaphylaxis may be increasing, but rates of fatal anaphylaxis to venom and food are stable. Risk factors for fatal anaphylaxis vary according to cause. For fatal drug anaphylaxis, previous cardiovascular morbidity and older age are risk factors, with beta-lactam antibiotics, general anesthetic agents, and radiocontrast injections the commonest triggers. Fatal food anaphylaxis most commonly occurs during the second and third decades. Delayed epinephrine administration is a risk factor; common triggers are nuts, seafood, and in children, milk. For fatal venom anaphylaxis, risk factors include middle age, male sex, white race, cardiovascular disease, and possibly mastocytosis; insect triggers vary by region. Upright posture is a feature of fatal anaphylaxis to both food and venom. The rarity of fatal anaphylaxis and the significant quality of life impact of allergic conditions suggest that quality of life impairment should be a key consideration when making treatment decisions in patients at risk for anaphylaxis.",
keywords = "Anaphylaxis, Drug allergy, Food allergy, Insect sting, Mortality",
author = "Turner, {Paul J.} and Elina Jerschow and Thisanayagam Umasunthar and Robert Lin and Campbell, {Dianne E.} and Boyle, {Robert J.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1016/j.jaip.2017.06.031",
language = "English (US)",
volume = "5",
pages = "1169--1178",
journal = "Journal of Allergy and Clinical Immunology: In Practice",
issn = "2213-2198",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Fatal Anaphylaxis

T2 - Mortality Rate and Risk Factors

AU - Turner, Paul J.

AU - Jerschow, Elina

AU - Umasunthar, Thisanayagam

AU - Lin, Robert

AU - Campbell, Dianne E.

AU - Boyle, Robert J.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Up to 5% of the US population has suffered anaphylaxis. Fatal outcome is rare, such that even for people with known venom or food allergy, fatal anaphylaxis constitutes less than 1% of total mortality risk. The incidence of fatal anaphylaxis has not increased in line with hospital admissions for anaphylaxis. Fatal drug anaphylaxis may be increasing, but rates of fatal anaphylaxis to venom and food are stable. Risk factors for fatal anaphylaxis vary according to cause. For fatal drug anaphylaxis, previous cardiovascular morbidity and older age are risk factors, with beta-lactam antibiotics, general anesthetic agents, and radiocontrast injections the commonest triggers. Fatal food anaphylaxis most commonly occurs during the second and third decades. Delayed epinephrine administration is a risk factor; common triggers are nuts, seafood, and in children, milk. For fatal venom anaphylaxis, risk factors include middle age, male sex, white race, cardiovascular disease, and possibly mastocytosis; insect triggers vary by region. Upright posture is a feature of fatal anaphylaxis to both food and venom. The rarity of fatal anaphylaxis and the significant quality of life impact of allergic conditions suggest that quality of life impairment should be a key consideration when making treatment decisions in patients at risk for anaphylaxis.

AB - Up to 5% of the US population has suffered anaphylaxis. Fatal outcome is rare, such that even for people with known venom or food allergy, fatal anaphylaxis constitutes less than 1% of total mortality risk. The incidence of fatal anaphylaxis has not increased in line with hospital admissions for anaphylaxis. Fatal drug anaphylaxis may be increasing, but rates of fatal anaphylaxis to venom and food are stable. Risk factors for fatal anaphylaxis vary according to cause. For fatal drug anaphylaxis, previous cardiovascular morbidity and older age are risk factors, with beta-lactam antibiotics, general anesthetic agents, and radiocontrast injections the commonest triggers. Fatal food anaphylaxis most commonly occurs during the second and third decades. Delayed epinephrine administration is a risk factor; common triggers are nuts, seafood, and in children, milk. For fatal venom anaphylaxis, risk factors include middle age, male sex, white race, cardiovascular disease, and possibly mastocytosis; insect triggers vary by region. Upright posture is a feature of fatal anaphylaxis to both food and venom. The rarity of fatal anaphylaxis and the significant quality of life impact of allergic conditions suggest that quality of life impairment should be a key consideration when making treatment decisions in patients at risk for anaphylaxis.

KW - Anaphylaxis

KW - Drug allergy

KW - Food allergy

KW - Insect sting

KW - Mortality

UR - http://www.scopus.com/inward/record.url?scp=85028994403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028994403&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2017.06.031

DO - 10.1016/j.jaip.2017.06.031

M3 - Article

C2 - 28888247

AN - SCOPUS:85028994403

VL - 5

SP - 1169

EP - 1178

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

SN - 2213-2198

IS - 5

ER -